EP1592715A1 - Gels solubles et biocompatibles d'acide hyalonurique reticule avec des l-acides amines ou des l-aminoesters bifonctionnels - Google Patents

Gels solubles et biocompatibles d'acide hyalonurique reticule avec des l-acides amines ou des l-aminoesters bifonctionnels

Info

Publication number
EP1592715A1
EP1592715A1 EP03815561A EP03815561A EP1592715A1 EP 1592715 A1 EP1592715 A1 EP 1592715A1 EP 03815561 A EP03815561 A EP 03815561A EP 03815561 A EP03815561 A EP 03815561A EP 1592715 A1 EP1592715 A1 EP 1592715A1
Authority
EP
European Patent Office
Prior art keywords
process according
hyaluronic acid
gel
comprised
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03815561A
Other languages
German (de)
English (en)
Inventor
Luigi Fratini
Maurizio Meldoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosphere SpA
Original Assignee
Biosphere SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosphere SpA filed Critical Biosphere SpA
Publication of EP1592715A1 publication Critical patent/EP1592715A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Definitions

  • the present invention refers to soluble, bio-compatible gels consisting of hyaluronic acid cross-linked with bi-functional L-aminoacids or L-aminoesters, or mixtures thereof, to a process for their preparation and to their use in the pharmaceutical, cosmetic surgical and medical fields.
  • Hyaluronic acid is a mucopolysaccharide consisting of alternated units of D- glucuronic acid and N-acetyl-glucosamine, bound together by ⁇ 1-3 and ⁇ -4 bindings.
  • Hyaluronic acid is found in nature in the synovial liquid of articular joints, in the vitreous humour of eyes, in the umbilical cordon and in the connective tissues.
  • Hyaluronic acid can be obtained by extraction from animal tissues like cockscombs or umbilical cordons, or can be recovered from the fermenting broth of specific Streptococci.
  • the present invention allows to overcome the above said problem by making available gels soluble in water and bio-compatible prepared by cross-linking hyaluronic acid with bi-functional L-aminoacids or L-aminoesters or their mixtures.
  • the characteristics of the compounds according to the invention make them ideal products for use in various fields from pharmaceutical to medical.
  • the product in the form of film or gel, can for example be used as anti-adherent material in surgery (in abdomen, spinal surgery etc); in this case the material forms a barrier separating the damaged tissues and is absorbed after a time which allows the formation of the new tissues.
  • the products according to the present invention can be also used as substrate for tissue engineering (derma, epidermis tissue, bones, fat cells, etc.) and can be used in ophthalmology, dermatology, in the osteoartritis field etc.
  • the compounds according to the invention can be prepared in water or in a mixture water/organic solvents as DMF or DMSO depending on their use.
  • the reaction is carried out in two subsequent steps: firstly the hyaluronic acid is activated and thereafter the binding between hyaluronic acid a cross-linking agent is performed.
  • the activation of hyaluronic acid takes place in the presence of a carbodiimide soluble in water according to known processes (see for example Tomihata, J. Biomed. Mater. Res., 1997, 37(2), 243-251; Danishefsky, Carbohydrate Res., 1971, 16, 199-205).
  • a carbodiimide soluble in water the N-3-dimethylamino-propylethylcarbodiimide hydrochloride is particularly preferred.
  • the cross-linking agents are bi-functional ⁇ L- amino acids, i.e. having a second functional group besides the amino acid group, or their esters or mixtures thereof.
  • Particularly preferred are L-lysine, L-serine, L- lysine ethylester di-hydrochloride, L-lysine methylester di-hydrochloride, L-serine methylester hydrochloride, L-serine ethylester hydrochloride or mixtures thereof.
  • the use of amino esters instead of amino acids allows the protection of the carboxylic functions of the amino acids in respect of their possible activation and their involvement in secondary reactions.
  • the reaction is carried out in a reactor equipped with a stirring system and a temperature controller.
  • the hyaluronic acid sodium salt is dissolved in water in a concentration comprised between 0.5 and 2.5% according to the desired characteristics of the final product, the preferred concentration is 1 - 1.5%.
  • the reaction temperature is one of the essential condition for obtaining the products of the invention and it must be comprised between 0°C and 25°C, preferably between 0°C and 10°C.
  • the pH is brought at 3 - 6, preferably 4-5, for example by adding diluted HCl.
  • activating agent/hyaluronic acid sodium salt Another essential factor for obtaining the products according to the invention it is the ratio: activating agent/hyaluronic acid sodium salt; the activating agent must be added in quantities comprised between 0.05 - 0.5 equivalents for equivalent of monomer unit of hyaluronic acid, preferably between 0.1 and 0.2 equivalents. If higher quantities of activating agent are used irreversible binding between hyaluronic acid and activating agent takes place instead of the wanted binding hyaluronic acid/cross-linking agent which causes the formation of undesired products which are insoluble or partially insoluble in water and having bio- compatibility and purity characteristics which are different from those of the presently described products. Finally the cross-linking agent is added in quantities comprised between 0.1 - 1 equivalents for equivalent of monomer unit of starting hyaluronic acid.
  • reaction mixture is kept at the fixed temperature and under stirring for 15 minutes - 4 hours, preferably 30 minutes - 2 hours.
  • a solution of NaCl 1 M is added and a buffer solution at pH 7 - 8 (preferably 7.5) then the mixture is purified according to known techniques as dialysis and/or diafiltration on ultrafiltration membrane and/or precipitation with an organic solvent and/or evaporation under vacuum and/or freeze drying.
  • the preferred methods are diafiltration on membrane having a cutoff of 30 KDa and freeze drying.
  • the solid product can be solved in water or in physiologic solution in various concentrations in order to obtain viscous solutions or transparent gels, it is also possible to obtain thin films, membranes according to the wanted use.
  • the product can be sterilised for example by filtration at 0.2 ⁇ .
  • the reciprocal quantities hyaluronic acid/activating agent/cross-linking agent have an effect on the cross-linking grade and therefore they will be chosen according to the wanted viscoelastic properties. Obviously the final characteristics will also be a consequence of the hyaluronic acid used as starting product.
  • hyaluronic acid having higher molecular weight will result in a liquid more viscous and compact compared to the one obtained with a hyaluronic acid having lower molecular weight.
  • hyaluronic acid having a molecular weight comprised between 100.000 and 2.000.000 is used and the final products will have a molecular weight comprised between 200.000 and 2.500.000.
  • the final products have a cross-linking degree of 2 - 40%.
  • hyaluronic acid sodium salt (MW 1.550.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.048 g (0.1 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.31 g (0.5 eq) of L-lysine ethylesterdi- hydrochloride are added.
  • hyaluronic acid sodium salt (MW 1.550.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.096 g (0.2 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.31 g (0.5 eq) of L-lysine ethylesterdi- hydrochloride are added.
  • hyaluronic acid sodium salt (MW 750.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.048 g (0.1 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.20 g (0.5 eq) of L-serine methylester hydrochloride are added.
  • hyaluronic acid sodium salt (MW 750.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.096 g (0.2 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.20 g (0.5 eq) of L-serine methylester hydrochloride are added.
  • hyaluronic acid sodium salt (MW 1.600.000) (2.5 mmol) are dissolved in 100 ml of demineralised water. The temperature is maintained at 5°C and the pH value is brought to 4.5 by addition of diluted HCl. 0.048 g (0.1 eq) of N-3-dimethylamino- propylethylcarbodiimide hydrochloride and 0.18 g (0.5 eq) of L-lysine are added.
  • Example 1 The solid obtained in Example 1 is dissolved in water in a concentration of 3-4g/l and filtered, under sterile condition, at 0.2 microns.
  • the filtered gel is sterile and has a content of endotoxines lower than 0.2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne des gels solubles et biocompatibles d'acide hyalonurique réticulé avec des L-acides aminés ou des L-aminoesters bifonctionnels ou un mélange de ceux-ci, ainsi qu'un procédé permettant de préparer ces gels, et leur utilisation dans les domaines pharmaceutique, cosmétique et médico-chirurgical.
EP03815561A 2003-01-31 2003-01-31 Gels solubles et biocompatibles d'acide hyalonurique reticule avec des l-acides amines ou des l-aminoesters bifonctionnels Withdrawn EP1592715A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/000321 WO2004067575A1 (fr) 2003-01-31 2003-01-31 Gels solubles et biocompatibles d'acide hyalonurique reticule avec des l-acides amines ou des l-aminoesters bifonctionnels

Publications (1)

Publication Number Publication Date
EP1592715A1 true EP1592715A1 (fr) 2005-11-09

Family

ID=32800540

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03815561A Withdrawn EP1592715A1 (fr) 2003-01-31 2003-01-31 Gels solubles et biocompatibles d'acide hyalonurique reticule avec des l-acides amines ou des l-aminoesters bifonctionnels

Country Status (3)

Country Link
EP (1) EP1592715A1 (fr)
AU (1) AU2003303820A1 (fr)
WO (1) WO2004067575A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2636998T3 (es) 2004-11-24 2017-10-10 Albumedix A/S Método de reticulación de ácido hialurónico con divinil sulfona
JP5523338B2 (ja) 2007-12-19 2014-06-18 エヴォニク ゴールドシュミット ゲーエムベーハー エマルジョン中の架橋ヒアルロン酸
EP3184552B1 (fr) 2008-09-02 2020-08-12 Tautona Group LP Fils d'acide hyaluronique, leurs procédés de fabrication et leurs utilisations
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
DK3078388T3 (da) 2010-03-22 2019-05-20 Allergan Inc Tværbundne hydrogeler til blødvævsforøgelse
WO2011148116A2 (fr) * 2010-05-27 2011-12-01 Laboratoire Idenov Acide hyaluronique modifie, procede de fabrication et utilisations
US20130096081A1 (en) * 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
CN107412002A (zh) 2011-06-03 2017-12-01 阿勒根公司 包括抗氧化剂的皮肤填充剂组合物
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) * 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
CN104105474B (zh) * 2011-09-14 2018-04-06 阿勒根公司 用于细纹治疗的真皮填充剂组合物
US20140315828A1 (en) 2013-04-22 2014-10-23 Allergan, Inc. Cross-linked silk-hyaluronic acid compositions
WO2016051219A1 (fr) 2014-09-30 2016-04-07 Allergan Industrie, Sas Compositions d'hydrogel stables pourvues d'additifs
EP3503841A4 (fr) 2016-08-24 2020-04-22 Allergan, Inc. Hydrogels co-réticulés d'acide hyaluronique-fibroïne pour améliorer la viabilité des greffes tissulaires et pour l'augmentation des tissus mous
US20230190997A1 (en) 2017-06-26 2023-06-22 Evolved By Nature, Inc. Silk-hyaluronic acid based tissue filers and methods of using the same
LU101045B1 (en) * 2018-12-11 2020-06-11 Qventis GmbH Method for the manufacture and use of a bionic hydrogel composition for medical applications

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
IT1317091B1 (it) * 2000-02-08 2003-05-26 S F I R Societa Fondaria Ind R Gel di acido ialuronico cross-linked con l-amminoacidi ol-amminoesteri bifunzionali.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004067575A1 *

Also Published As

Publication number Publication date
WO2004067575A1 (fr) 2004-08-12
AU2003303820A1 (en) 2004-08-23

Similar Documents

Publication Publication Date Title
US6610669B1 (en) Water insoluble derivatives of polyanionic polysaccharides
WO2004067575A1 (fr) Gels solubles et biocompatibles d'acide hyalonurique reticule avec des l-acides amines ou des l-aminoesters bifonctionnels
US6831172B1 (en) Cross-linked hyaluronic acids and medical uses thereof
US6174999B1 (en) Water insoluble derivatives of polyanionic polysaccharides
DE69925733T2 (de) Hyaluronsäureamide und ihre derivate und ein verfahren zu deren herstellung
KR101587521B1 (ko) 소수성 알코올 유도체에 의해 치환된 카복실 관능기를 포함하는 폴리사카라이드
US6235726B1 (en) Water insoluble derivatives of polyanionic polysaccharides
US6030958A (en) Water insoluble derivatives of hyaluronic acid
AU2001246418B2 (en) Gels of hyaluronic acid cross-linked with bi-functional L-aminoacids or L-aminoesters or mixtures thereof
AU2001246418A1 (en) Gels of hyaluronic acid cross-linked with bi-functional L-aminoacids or L-aminoesters or mixtures thereof
CN113929792B (zh) 一种醛基化修饰的透明质酸(钠)及其合成方法和应用
KR20170075723A (ko) 글리코사미노글리칸 및 단백질을 함유하는 조성물
ITFI20010243A1 (it) Gel solubili e biocompatibili di acido ialuronico cross-linked con l-amminoacidi o l-amminoesteri bifunzionali
MXPA01004712A (en) Cross-linked hyaluronic acids and medical uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20061204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090721